2025 Non-GAAP Guidance: Initiated 2025 non-GAAP guidance at $3.53–$3.65 per share, contingent upon the outcome of the Montana ...

Guidance for full-year 2025 product revenue and adjusted EBITDA was increased as prescription growth from ADHD drug Jornay PM accelerates, with prescriptions up 23% year-over-year. These 10 stocks ...

Key Points Non-GAAP earnings per share reached $0.52 for Q2 2025, beating expectations by $0.01, but revenue (GAAP) fell 4.9% year over year. US sales declined 18.3% (GAAP), leading to a $214 million ...

Synergy realization from the Care REIT integration remains on track, with management indicating that approximately 50% of the ...

Q2 2025 Management View Alan E. Baratz, President, CEO & Director, highlighted the launch and general availability of the Advantage2 quantum computer, describing it as "our most advanced and ...